Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -4 of 4
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
Oral Neurokinin-1 Antagonist, Aprepitant, in Combination With Ondansetron and Dexamethasone in Patients Undergoing Autologous Peripheral Blood Stem Cell Transplantation
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV
Supportive care
Active
18 and over
Other
hsc 031192
ind 70268, NCT00285272
Last Modified:
6/10/2008
 
First Published:
7/1/2002
2.
Phase II/III Randomized Study of Ginger for Chemotherapy-Related Nausea in Patients With Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Supportive care
Active
18 and over
NCI
URCC-U1902
URCC-0114, NCI-5857, NCI-P02-0223, NCT00040742
3.
Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic Chemotherapy
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Supportive care
Active
18 and over
Pharmaceutical / Industry
NKV101983
NCT00104403
Last Modified:
4/29/2008
 
First Published:
6/16/2006
4.
Study of Dexamethasone in Combination With Either Ondansetron or Palonosetron Hydrochloride in Preventing Acute and Delayed Chemotherapy-Induced Nausea and Vomiting in Patients With Early-Stage Breast Cancer Undergoing Chemotherapy Comprising Doxorubicin Hydrochloride and Cyclophosphamide
Phase
Type
Status
Age
Sponsor
Protocol IDs
No phase specified
Supportive care, Treatment
Active
18 and over
NCI, Pharmaceutical / Industry
UWCC-UW-6140
UWCC-05-9579-H/D, FHCRC-6140, MGI-FHCRC-6140, NCT00343863
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute